Sharing is caring!

Eureka Therapeutics Commences Phase I Clinical Trials for T-Cell Therapy. 

Eureka Therapeutics has commenced enrolling adults with advanced hepatocellular carcinoma (HCC) in a Phase 1/2 trial of its investigational ET140203 T-cell therapy.

They plan to enroll around 50 patients whose tumors contain alpha-fetoprotein (AFP), a protein that is overly produced by some types of malignant cells, including liver cancer cells.

The study will be divided into two phases. The first phase will assess the safety and efficacy of increasing doses of ET140203 to determine the best dose to be used in the next phase of the study over the course of 28 days.  In the second phase, the therapy will be assessed by its efficacy and pharmacokinetic properties over the course of 2 years.

ET140203 contains patient-derived immune T-cells that have been genetically modified to target and destroy cancer cells containing AFP protein complexes.

(Source: Immuno-Oncology News, 2020)

Bone Therapeutics, Link Health Pharma and Shenzhen Pregene Biopharma enter into an exclusive license agreement for cell therapy platform. 

Bone Therapeutics, Link Health Pharma Co., Ltd, and Shenzhen Pregene Biopharma Company recently announced that they have come together in an exclusive license agreement for the manufacturing, clinical development, and commercialization of Bone Therapeutics’ allogeneic, off-the-shelf, bone cell therapy platform ALLOB in China, Hong Kong, Taiwan, Singapore, South Korea, and Thailand markets.

Under the agreement, Bone Therapeutics is eligible to receive up to $64.6 million in development, regulatory, and commercial milestone payments including $11.7 million in upfront and milestone payments anticipated in the next year. Bone Therapeutics is also entitled to receive tiered double-digit royalties on annual net sales of ALLOB.

(Source: Global News Wire, 2020)

Avrobio licenses its Gene Therapy for treating Hunter syndrome. 

Avrobio has recently licensed a Hunter syndrome lentiviral gene therapy from the University of Manchester. The deal positions Avrobio to join Regenxbio and Sangamo Therapeutics in the race to develop gene therapies for use in patients with Hunter syndrome.

Hunter syndrome, also known as mucopolysaccharidosis Type II, is driven by a mutation that limits a patient’s ability to break down sugar molecules generated as a byproduct of cell activity, leading to progressive damage to organs such as the brain which affects the development of children with the lysosomal disorder.

Avrobio’s gene therapy, AVR-RD-05 will modify a patient’s hematopoietic stem cells with a transgene for IDS expression and a protein tag intended to improve the stability of the enzyme.

(Source: Fierce Biotech, 2020)